We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00477308
Recruitment Status : Completed
First Posted : May 23, 2007
Last Update Posted : June 7, 2010
Sponsor:
Collaborator:
Swiss Cohort
Information provided by:
The HIV Netherlands Australia Thailand Research Collaboration

Brief Summary:
In HIV-NAT 013 phase I study, genotyping was performed in 95 children on dual NRTI which showed that almost all children had resistance to NRTi. The HIV-NAT 013 phase II is a follow up study to evaluate treatment outcome after salvage therapy and the evolution of mutations.

Condition or disease Intervention/treatment Phase
HIV Infections Procedure: salvage therapy Phase 4

Detailed Description:

The HIV-NAT 013 study (conducted in 2003) evaluated prevalence and pattern of RT mutation in 95 children treated with dual NRTI. The study showed almost all children to have some degree of NRTI resistance and 40% with multi NRTI resistance. The mutation reported was major mutation.

After the study, the patients were managed based on the physician's judgment using genotyping results. The 95 patients in HIV-NAT 013 are categorized into 3 groups.

  1. No viral resistance
  2. Low grade resistance with or without clinical/ immunological failure
  3. High grade resistance with or without clinical/ immunological failure.

There are limited prospective studies evaluating outcome of decision regarding salvage therapy after genotyping results

There are also new mutations that are not considered major mutation that may affect treatment outcome

Knowledge learned from this study will benefit Thai children with NRTI resistance by helping pediatricians better choose salvage treatment options


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical, Immunologic and Virological Outcomes of Genotyping Directed Salvage Therapy in Children Who Have Failed Dual NRTIs
Study Start Date : January 2006
Primary Completion Date : April 2009
Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources




Primary Outcome Measures :
  1. Clinical, immunologic and virologic outcome of children who had genotyping directed salvage therapy [ Time Frame: 1 time point (Cross Sectional Study) ]

Secondary Outcome Measures :
  1. Comparison outcome of children in the 3 groups, [ Time Frame: 1 time point ]
  2. Changes of mutation in children within the 3 groups, and [ Time Frame: 1 time point ]
  3. Effect of previously unreported mutations, minor and others, on treatment outcome [ Time Frame: 1 time point ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All children from HIV-NAT 013 phase I

Exclusion Criteria:

  • No inform consent obtained

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00477308


Locations
Thailand
Chulalongkorn Hospital
Bangkok, Thailand, 10330
Queen Sirikit National Institute of Child Health, Bangkok
Bangkok, Thailand, 10330
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Bangkok, Thailand, 10330
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Swiss Cohort
Investigators
Principal Investigator: Kiat Ruxrungtham, MD The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Principal Investigator: Tawee Chotpitayasunondh, MD Queen Sirikit National Institute of Child Health, Bangkok

Additional Information:
Publications:
Responsible Party: Kiat Ruxrungtham, HIV-NAT
ClinicalTrials.gov Identifier: NCT00477308     History of Changes
Other Study ID Numbers: HIV-NAT 013 phase II
First Posted: May 23, 2007    Key Record Dates
Last Update Posted: June 7, 2010
Last Verified: June 2010

Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
HIV children
genotypic resistance
dual NRTIs
Salvage therapy
treatment outcome
Salvage therapy based on genotyping results
Treatment Failure

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases